AU2019379167B2 - Method of improving prediction of response for cancer patients treated with immunotherapy - Google Patents

Method of improving prediction of response for cancer patients treated with immunotherapy

Info

Publication number
AU2019379167B2
AU2019379167B2 AU2019379167A AU2019379167A AU2019379167B2 AU 2019379167 B2 AU2019379167 B2 AU 2019379167B2 AU 2019379167 A AU2019379167 A AU 2019379167A AU 2019379167 A AU2019379167 A AU 2019379167A AU 2019379167 B2 AU2019379167 B2 AU 2019379167B2
Authority
AU
Australia
Prior art keywords
hla
loh
tumor
tmb
mhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019379167A
Other languages
English (en)
Other versions
AU2019379167A1 (en
Inventor
Gustavo CERQUEIRA
Nicholas C. Dracopoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Personal Genome Diagnostics Inc
Original Assignee
Personal Genome Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Personal Genome Diagnostics Inc filed Critical Personal Genome Diagnostics Inc
Publication of AU2019379167A1 publication Critical patent/AU2019379167A1/en
Application granted granted Critical
Publication of AU2019379167B2 publication Critical patent/AU2019379167B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019379167A 2018-11-15 2019-11-15 Method of improving prediction of response for cancer patients treated with immunotherapy Active AU2019379167B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767979P 2018-11-15 2018-11-15
US62/767,979 2018-11-15
PCT/US2019/061710 WO2020102674A1 (en) 2018-11-15 2019-11-15 Method of improving prediction of response for cancer patients treated with immunotherapy

Publications (2)

Publication Number Publication Date
AU2019379167A1 AU2019379167A1 (en) 2021-06-03
AU2019379167B2 true AU2019379167B2 (en) 2026-05-14

Family

ID=70727341

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019379167A Active AU2019379167B2 (en) 2018-11-15 2019-11-15 Method of improving prediction of response for cancer patients treated with immunotherapy

Country Status (6)

Country Link
US (2) US12497661B2 (cg-RX-API-DMAC7.html)
EP (1) EP3880246A4 (cg-RX-API-DMAC7.html)
JP (2) JP7623281B2 (cg-RX-API-DMAC7.html)
AU (1) AU2019379167B2 (cg-RX-API-DMAC7.html)
CA (1) CA3120200A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020102674A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116134155A (zh) * 2020-08-26 2023-05-16 瑞泽恩制药公司 通过施用pd-1抑制剂治疗癌症的方法
CN111979323A (zh) * 2020-08-28 2020-11-24 深圳裕策生物科技有限公司 用于预测肿瘤免疫治疗效果的生物标志物检测方法及系统
CN112029861B (zh) * 2020-09-07 2021-09-21 臻悦生物科技江苏有限公司 基于捕获测序技术的肿瘤突变负荷检测装置及方法
JP2024516230A (ja) * 2021-04-30 2024-04-12 ジェネンテック, インコーポレイテッド がんのための治療及び診断方法並びに組成物
WO2023196390A1 (en) * 2022-04-06 2023-10-12 Foundation Medicine, Inc. Aneuploidy biomarkers associated with response to anti-cancer therapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183928A1 (en) * 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Methods of treating tumor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69933661T3 (de) * 1998-04-15 2012-01-26 Merck Serono Biodevelopment Genomische sequenz des 5-lipoxygenase-aktivierenden proteins (flap), polymorphische marker und ihre anwendung in der diagnose von asthma
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
EP3327148B1 (en) * 2010-06-18 2021-03-17 Myriad Genetics, Inc. Methods of predicting the status of brca1 and brca2 genes in a cancer cell
KR20170080697A (ko) * 2014-11-13 2017-07-10 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
MX381241B (es) 2015-04-27 2025-03-12 Cancer Research Tech Ltd Composición de células t para usarse en el tratamiento del cáncer.
US10563266B2 (en) 2015-07-14 2020-02-18 Personal Genome Diagnostics Inc. Neoantigen treatment prioritization using multivariate analysis based on: HLA genotype, self-similarity, similarity to known antigens, antigen expression levels and mutant allele frequency
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
WO2017151502A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
US11725247B2 (en) * 2016-02-29 2023-08-15 Foundation Medicine, Inc. Methods of treating cancer
WO2017151524A1 (en) * 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods and systems for evaluating tumor mutational burden
US20190247435A1 (en) 2016-06-29 2019-08-15 The Johns Hopkins University Neoantigens as targets for immunotherapy
US11332530B2 (en) 2016-09-23 2022-05-17 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
US20190240257A1 (en) 2016-10-13 2019-08-08 The Johns Hopkins University Compositions and methods for identifying functional anti-tumor t cell responses
US11634777B2 (en) * 2017-01-13 2023-04-25 The General Hospital Corporation Resistance to checkpoint blockade therapy
AU2018338441B2 (en) * 2017-09-25 2025-08-14 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183928A1 (en) * 2017-03-31 2018-10-04 Bristol-Myers Squibb Company Methods of treating tumor

Also Published As

Publication number Publication date
JP2025000809A (ja) 2025-01-07
EP3880246A1 (en) 2021-09-22
CA3120200A1 (en) 2020-05-22
JP7623281B2 (ja) 2025-01-28
US20200157642A1 (en) 2020-05-21
EP3880246A4 (en) 2022-08-10
JP2022513068A (ja) 2022-02-07
US12497661B2 (en) 2025-12-16
WO2020102674A1 (en) 2020-05-22
AU2019379167A1 (en) 2021-06-03
US20260071282A1 (en) 2026-03-12

Similar Documents

Publication Publication Date Title
US20260071282A1 (en) Method of improving prediction of response for cancer patients treated with immunotherapy
Dushyanthen et al. Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
Castelli et al. A comprehensive study of polymorphic sites along the HLA-G gene: implication for gene regulation and evolution
Biran et al. The genetics of alopecia areata: new approaches, new findings, new treatments
Pagadala et al. Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response
AU2019346023B2 (en) Method for selecting neoepitopes
US20220154295A1 (en) Methods and materials for assessing and treating cancer
WO2020221783A1 (en) Methods for pre-selection of neoepitopes
Malheiros et al. Genome‐wide gene expression profiling reveals unsuspected molecular alterations in pemphigus foliaceus
JP2025019066A (ja) 癌の免疫療法のための複合バイオマーカー
Hackett et al. A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors
Li et al. Integrated genomic characterization of the human immunome in cancer
López‐Villalobos et al. Association of CD 28 and CTLA 4 haplotypes with susceptibility to primary Sjögren′ s syndrome in Mexican population
Chen et al. A cis‐eQTL of HLA‐DRB1 and a frameshift mutation of MICA contribute to the pattern of association of HLA alleles with cervical cancer
Luo et al. Positive association of major histocompatibility complex class I chain‐related gene A polymorphism with leukemia susceptibility in the people of Han nationality of Southern China
Lautert-Dutra et al. Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer
JP2025066133A (ja) マイクロサテライト不安定性シグネチャー
Gong et al. Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy
Zhong et al. The necessary role of an efficient tumor immunotherapy by MHC II expression on amateur APCs
Goli et al. Human Leukocyte Antigen Determinants in Myocarditis and Dilated Cardiomyopathy
RU2826184C2 (ru) Способ отбора неоэпитопов
Pieper Impact of IFN-γ resistance & MAPK inhibition on the immune surveillance of malignant melanoma-relevance for immune-based therapies
Rawal et al. Major Histocompatibility Complex Dmα/β Genes and Their Expressional Diversity in Healthy and Diseased Water Buffalo Bubalus bubalis
Safonov Molecular And Genetic Properties Of Breast Cancer Associated With Local Immune Activity
HK40013532A (en) Ranking system for immunogenic cancer-specific epitopes